

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-460**

**CORRESPONDENCE**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 21-460

Bristol-Myers Squibb  
Attention: Warren Randolph  
U.S. Regulatory Liaison, Worldwide Reg. Affairs  
P.O. Box 4000  
Princeton, NJ 08543-4000

Dear Mr. Randolph:

Please refer to your new drug application (NDA) for Glipizide/Metformin hydrochloride Tablets submitted and received on December 21, 2001.

An acknowledgement letter dated January 7, 2002 was issued for this NDA. The letter stated that the Agency would notify you within 60 days of receipt of the NDA if the application is sufficiently complete to permit a substantive review. The date by which time this determination would be made was erroneously stated as February 5, 2002.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on **February 19, 2002** in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be October 21, 2002.

The above details were discussed by telephone on January 9, 2002 between Warren Randolph and James Cross of this Division.

If you have any questions, call me at 301-827-6381.

Sincerely,

*{See appended electronic signature page}*

James T. Cross  
Regulatory Project Manager  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

-----  
James Cross

1/10/02 01:18:38 PM



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 21-460

Bristol-Myers Squibb Pharmaceutical Research Institute  
Attention: Warren Randolph  
P.O. Box 4000  
Princeton, NJ 08543-4000

Dear Mr. Randolph:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Glipizide/metformin hydrochloride Tablets  
Review Priority Classification: Standard (S)  
Date of Application: December 21, 2001  
Date of Receipt: December 21, 2001  
Our Reference Number: NDA 21-240

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on February 5, 2002 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be October 21, 2002.

Please cite the NDA number listed above at the top of the first page of any communications concerning this application. Address all communications concerning this NDA as follows:

U.S. Postal Service/Courier/Overnight Mail:  
Center for Drug Evaluation and Research  
Division of Metabolic and Endocrine Drug Products, HFD-510  
Attention: Division Document Room, 14B-19  
5600 Fishers Lane  
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6381.

Sincerely,

*{See appended electronic signature page}*

James T. Cross  
Regulatory Project Manager, HFD-510  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

James Cross

1/7/02 03:33:30 PM



Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Drug Evaluation II

---

**FACSIMILE TRANSMITTAL SHEET**

---

**DATE:** October 10, 2002

<b>To:</b> Warren Randolph	<b>From:</b> James Cross <i>{see electronic signature page}</i>
<b>Company:</b> Bristol-Myers Squibb	Division of Division of Metabolic and Endocrine Drug Products
<b>Fax number:</b> 609-252-6000	<b>Fax number:</b> 301-443-9282
<b>Phone number:</b> 609-252-5228	<b>Phone number:</b> (301) 827-6381
<b>Subject:</b> Biopharmaceutic comments for new drug application 21-460, fixed-dose combination product, "Metaglip," (glipizide/metformin). <b>Postmarketing dissolution study commitment required.</b>	

**Total no. of pages including cover:** 3

**Comments:** Please read attached biopharmaceutic comments regarding your pending NDA (submitted December 21, 2002). If you have any questions, do not hesitate do contact the Division. This fax contains a description of the dissolution study for which a commitment to conduct the study is required prior to approval of your pending application.

---

**Document to be mailed:** YES  NO

---

**THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.**

**If you are not the addressee, or a person authorized to deliver this document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us immediately by telephone at (301) 827-6430. Thank you.**

**BIOPHARMACEUTIC POSTMARKETING (PHASE 4) STUDY COMMITMENT:**

The use of a pH — medium for the dissolution of glipizide/metformin HCl combination tablets was found to be unacceptable by the Agency. Data submitted in this application suggests that a pH 6.8 medium should be further investigated and instituted as the regulatory dissolution method. Please provide multipoint dissolution data on each of the tablet strengths using a pH 6.8 dissolution medium. The current method will be excepted on an interim basis only. Results from the requested study should be presented to the Agency within 6 months of the Action Letter date for this application.

Your response to our request for this postmarketing study commitment must also provide information on the following aspects of the commitment:

Protocol Submission:	Within X months of the date of the action letter.
Study Start:	Within Y months of the date of the action letter.
Final Report Submission:	Within 6 months of the date of the action letter.

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

-----  
James Cross

10/10/02 03:29:37 PM

CSO